Back

Beta-blocker interruption or continuation after myocardial infarction? a systematic review and meta-analysis

30 August 2025 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in acute coronary syndromes (2) Treatment ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Caroline Fischer Bacca

University Center for the Development of Alto Vale - UNIDAVI, Rio do Sul (Brazil)

5 More presentations in this session

Presentation thumbnail
Aspirin does not not associate with lower risk of major cardiovascular events or increased risk of bleeding in older individuals undergoing cardiac computed tomography angiography
Mr N. Kromann Noehr (Aalborg, DK)
Abstract Slides Video
Presentation thumbnail
Breathing patterns and ventilator efficiency in patients with acute coronary syndrome receiving ticagrelor - an analysis of the Bern Rehab Registry
Doctor A. Von Hardenberg (Bern, CH)
Abstract Slides
Presentation thumbnail
Colchicine in acute coronary syndrome: an updated meta-analysis of randomized controlled trials
Doctor K. Hosseini (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Clinical outcomes after stent thrombosis in patients with hemodialysis: from the Real-ST registry
Doctor Y. Kakimoto (Saga, JP)
Abstract Slides Video
Presentation thumbnail
Intravenous nicorandil during primary percutaneous coronary intervention for acute myocardial infarction
Doctor J. Ge (Shanghai, CN)
Slides

Access the full session

Session thumbnail
Pharmacotherapy in acute coronary syndromes (2)

The Event

Event poster

ESC Congress 2025

30 August 2025 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Mortality effects of beta-blockers on myocardial infarction in patients without reduced ejection fraction or heart failure in the contemporary reperfusion era : a systematic review and meta-analysis
thumbnail
Congress Presentation
Clinical outcomes of beta-blocker therapy after myocardial infarction in patients with preserved or mildly reduced ejection fraction
thumbnail
Congress Presentation
HOT LINES from ESC Congress 2024: what is new in TAVI and mitral valve repair?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources